Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01281189 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study of Dexpramipexole in ALS
A Phase 3 study, sponsored by Knopp Biosciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 942
- Enrollment target
NCT01281189 is a Phase 3 study that has completed, run by Knopp Biosciences. The registered enrollment target is 942 participants.
The verdict
NCT01281189, a Phase 3 study, has completed, sponsored by Knopp Biosciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 942 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether dexpramipexole (150 mg twice daily) is safe and effective in the treatment of Amyotrophic Lateral Sclerosis (ALS).
Interventions
- DRUG Placebo
- DRUG Dexpramipexole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 942 participants |
| Start Date | 2011-03 |
| Est. Completion | 2012-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01281189
The ClinicalTrials.gov registry entry for NCT01281189 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 942 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Knopp Biosciences, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01281189 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01281189 about?
NCT01281189 is a clinical study titled "Phase 3 Study of Dexpramipexole in ALS". The purpose of this study is to determine whether dexpramipexole (150 mg twice daily) is safe and effective in the treatment of Amyotrophic Lateral Sclerosis (ALS).
What is the current status of trial NCT01281189?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 942 participants. The study started on 2011-03. Estimated completion is 2012-11.
What interventions are being tested in trial NCT01281189?
The interventions under investigation include: Placebo (DRUG), Dexpramipexole (DRUG).
Who is sponsoring clinical trial NCT01281189?
This trial is sponsored by Knopp Biosciences, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.